Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
4 Articles
4 Articles
Weatherford Democrat
Jonesboro SunXenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology
Xenetic and Santersus enter into definitive share exchange agreement - BioTuesdays
Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected to trade on the Nasdaq Capital Market as Santersus Bio, Inc. under new ticker symbol SNTS. According to Xenetic, the transaction is expected to create […]
The transaction is intended to create a company listed on Nasdaq at the clinical stage for several indications focused on the targeted fight against neutrophils extracellular traps (NETs) – a disease trigger in the fields of intensive care medicine, autoimmune diseases, transplantation and oncology The merger of the two companies will result in the NucleoCapture® technology from Santersus, which is based on it.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
